BRIEF-Aurinia announces that voclosporin achieves endpoints in its Phase IIB Aura-LV Study
Sept 29 (Reuters) - Aurinia Pharmaceuticals Inc
* Comprehensive mortality review concludes deaths in aura-lv study appear to be unrelated to study drug and consistent with complications of ln
* Announces that Voclosporin achieves primary and all pre-specified secondary endpoints in its phase IIB Aura-LV study for Lupus Nephritis (ln) Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.